ESPR - Esperion Therapeutics, Inc.

NasdaqGM - NasdaqGM 即時價格。貨幣為 USD。
+0.0200 (+1.48%)
收市:04:00PM EDT
1.3300 -0.04 (-2.92%)
收市後: 05:43PM EDT
買盤0.0000 x 3100
賣出價0.0000 x 1000
今日波幅1.3250 - 1.4450
52 週波幅1.1200 - 8.8700
Beta 值 (5 年,每月)0.12
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-3.2800
業績公佈日2023年7月31日 - 2023年8月04日
遠期股息及收益率無 (無)
1 年預測目標價10.19
  • InvestorPlace

    7 Very Undervalued Penny Stocks to Buy in April 2023

    Investors are attracted to penny stocks for their potential to provide exponential gains. It is very common to find such companies trading for fractions of their target price. It is also worth noting that penny stocks are highly risky and it goes without saying that losses aren’t uncommon. In other words, don’t treat these stocks the same as their more stable counterparts, and only invest what you can afford to lose. That said, the penny stocks listed here are interesting and fall, for the most

  • Benzinga

    Esperion Long Term Data On Cholesterol Medication's Ability To Cut Cardiovascular Risk Fails To Impress Investors

    Esperion Therapeutics Inc (NASDAQ: ESPR) announced the full results from the CLEAR Outcomes trial, a global study of nearly 14,000 patients with or at risk for cardiovascular disease who were unable to maximize or tolerate a statin. The study showed that Nexletol (Bempedoic acid) significantly reduced the risk of hard MACE-4 and MACE-3 by 13% and 15%, respectively, and significantly reduced the risk of heart attack and coronary revascularization by 23% and 19%, respectively, compared to placebo.

  • Benzinga

    Esperion Therapeutics Reports Sooner Than Expected Positive Data From Nexletol Trial

    Esperion Therapeutics Inc's (NASDAQ: ESPR) CLEAR Outcomes trial met its primary endpoint, demonstrating statistically significant risk reduction in MACE-4 in patients treated with 180 mg/day NEXLETOL (bempedoic acid) compared to placebo. The data demonstrate statistically significant and clinically meaningful results. The study included over 14,000 patients at over 1,200 sites in 32 countries. Bempedoic acid becomes the first ATP citrate lyase inhibitor and oral non-statin to meet the major adve